Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Cash & Equivalents (2024 - 2026)

Carlsmed filings provide 2 years of Cash & Equivalents readings, the most recent being $109.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 173.89% to $109.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.9 million, a 173.89% increase, with the full-year FY2025 number at $109.9 million, up 173.89% from a year prior.
  • Cash & Equivalents hit $109.9 million in Q4 2025 for Carlsmed, down from $115.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $115.4 million in Q3 2025 to a low of $33.5 million in Q2 2025.